Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 1355

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 1355
---
 not be successful, which could adversely affect
our ability to develop and commercialize our current and potential future product candidates.

We
may seek clinical supply or collaboration arrangements with biopharmaceutical companies for the development or commercialization of our
current and potential future product candidates. For example, in October 2024, we entered into a clinical supply agreement with BeiGene
to advance the clinical trial evaluation of Decoy20 in combination with BeiGene’s anti-PD-1 antibody, tislelizumab (the “BeiGene
Product”) for the treatment of patients with advanced solid tumors (the “Combination Study”). Under our agreement with
BeiGene, we will rely on BeiGene for the supply of the Beigene Product. If BeiGene cannot perform as agreed, we may be unable to initiate
or complete the Combination Study in a timely manner or at all.

To
the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators.
Moreover, collaboration arrangements are complex and time consuming to negotiate, execute and implement. We may not be successful in
our efforts to establish and implement collaborations or other alternative arrangements should we choose to enter into such arrangements,
and the terms of the arrangements may not be favorable to us. If and when we collaborate with a third party for development and commercialization
of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the
third party.

The
success of our clinical supply and collaboration arrangements will depend heavily on the efforts and activities of our collaborators.
Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations.

Disagreements
between parties to a clinical supply or collaboration arrangement can lead to delays in developing or commercializing the applicable
product candidate and can be difficult to resolve in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical
companies and other third parties are terminated or allowed to expire by the other party. Any such termination or expiration would adversely
affect our business, financial condition and results of operations.

If
we are unable to develop our own commercial organization or enter into agreements with third parties to sell and market our product candidates,
we may be unable to generate significant revenues.

We
do not have a sales and marketing organization, and we have no experience as a company in the sales, marketing and distribution of pharmaceutical
products. If any of our product candidates are ever approved for commercialization